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ABSTRACT
Introduction: Vasculo-Behcet’s disease is a
subtype of Behcet’s disease, characterized by
cases in which vascular complications are
present and often dominate the clinical
features. In this disease, there are four
different vascular complications: arterial
occlusion, arterial aneurysm or
pseudoaneurysm, venous thrombosis, and
variceal formation. It is rare that arterial
lesions are multiple, but without venous
involvement. So far, the optimal treatment of
the disease has not been established.
Case Report: The authors report a rare case of
vasculo-Behcet’s disease with multiple and
recurrent pseudoaneurysms in large arteries,
but without affecting the venous system. The
patient underwent three rounds of surgery, but
developed a new pseudoaneurysm after each
operation in short term. However, the patient
was successfully treated with a combination of
prednisone and immunosuppressive agents.
Conclusion: For Vasculo-Behcet’s disease,
surgical and endovascular interventions alone
increased the incidence of pseudoaneurysm.
Early diagnosis and early initiation of
prednisone in combination with
immunosuppressive therapy are critical for
inhibiting the progression of vascular lesions
and provide a good prognosis.
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INTRODUCTION
Behcet’s disease is a systemic vasculitis disorder
of unknown etiology, characterized by relapsing
episodes of oral aphthous ulcers, genital ulcers,
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ocular lesions, and skin lesions. It can affect
other systems, including vascular,
gastrointestinal, and neurological systems [1].
The concept of vasculo-Behcet’s disease has
been adopted for cases in which vascular
complications are present and often dominate
the clinical features [2]. It is not uncommon in
Behcet’s disease, with a prevalence of 12.8% in
China [3] and 14.3% in Turkey [4]. However,
only 3.6% of patients with Behcet’s disease have
symptoms that affect the large arteries [4]. In
most reports, arterial lesions are isolated and
frequently coexist with venous lesions; rarely,
there can be multiple lesions [4]. To the authors’
knowledge, the treatment of the disease is
difficult. In this paper, the authors reported a
rare case of vasculo-Behcet’s disease with
multiple and recurrent pseudoaneurysms in
large arteries, but without affecting the venous
system. Surgical therapy alone increased the
incidence of pseudoaneurysm. However,
the patient was successfully treated with
a combination of prednisone and
immunosuppressive agents instead of surgery.
METHODS
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, revised in 2000.
Informed consent was obtained from the
patient included in this study.
CASE REPORT
A 33-year-old Chinese male was admitted to the
surgical ward due to a pulsating subcutaneous
mass in the right subclavicular region over a
2-month period. The patient denied any history
of trauma or manipulation. The patient felt
progressive and intermittent numbness of the
right upper extremity caused by the rapidly
growing mass. A computed tomography (CT)
angiogram revealed a right subclavian artery
pseudoaneurysm of 4.5 cm 9 3.5 cm (Fig. 1a),
which was soon resected and an expanded
polytetrafluoroethylene (e-PTFE) vascular graft
was performed. Histology of the arterial wall
revealed inflammatory cell infiltrate (Fig. 2).
Two months later, the patient developed a
symptomatic recurrence at the surgical site.
A CT angiography revealed that there were
both proximal and distal anastomotic
pseudoaneurysms, 0.76 cm 9 0.87 cm and
4.45 cm 9 4.67 cm, respectively, at the right
subclavian artery (Fig. 1b). The two
anastomotic pseudoaneurysms were also
excised.
Four months after the second operation, the
patient suffered from persistent severe left
lumbago that responded poorly to analgesics.
An abdominal CT angiography revealed
aneurysmal dilatation of the upper abdominal
aorta and the celiac trunk (Fig. 1c). Moreover,
the left kidney and adrenal gland were
atrophied due to compression by aneurysmal
dilatation. Consequently, the patient
underwent another operation.
One month after the third operation, the
patient had a pseudoaneurysm of
2.35 cm 9 1.74 cm in the right
thoracoacromial artery (Fig. 1d). Because the
patient developed multiple and recurrent
aneurysms over a short time span, the patient
was admitted to the dermatological ward
instead of reoperation.
After admission, a detailed review of the
patient’s history revealed recurrent oral and
genital aphthous ulcers of 10-year duration. The
ulcers occurred at least eight times in a year and
were described as multiple painful lesions, each
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of which had a diameter of 2–5 mm. The patient
also had a history of recurrent pseudofolliculitis
on the neck and back for 7 years. Physical
examinations showed a pulsatile swelling in
the right axilla. Multiple pigmented macules
were seen on the neck and back (Fig. 3). The
pathergy test was positive. No oral or genital
lesions were detected. Neither eye disease nor
joint problems were evident. Laboratory
investigation revealed erythrocyte
sedimentation rate (ESR) of 119 mm/h
(reference range 0–15 mm/h) and C-reactive
protein (CRP) of 70 mg/L (reference range
0–8 mg/L). Serum immunoglobulin
electrophoresis showed that immunoglobulin
G (IgG) and immunoglobulin M (IgM) were
elevated. Antinuclear antibody and other
autoantibodies, such as antineutrophil
cytoplasmic antibody and anticardiolipin
antibody, were all negative. A thorough
checkup of the vascular system of the whole
body did not reveal any new significant
Fig. 1 Computed tomography angiography showing a right
subclavian artery pseudoaneurysm of 4.5 cm 9 3.5 cm (a);
the proximal and distal anastomotic pseudoaneurysms,
0.76 cm 9 0.87 cm and 4.45 cm 9 4.67 cm, respectively, at
the right subclavian artery (b); the aneurysmal dilatation of
abdominal aorta, and atrophied left kidney and adrenal
gland (c); a pseudoaneurysm of 2.35 cm 9 1.74 cm in the
right thoracoacromial artery (d)
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abnormality except for a pseudoaneurysm in
the right thoracoacromial artery. A diagnosis of
vasculo-Behcet’s disease was made based on
recurrent oral and genital aphthous ulcers,
pseudofolliculitis, pseudoaneurysms, and
pathergy test. As the disease was active, as
evidenced by high ESR, CRP, IgG, IgM,
positive pathergy test, and development of
fresh aneurysm, the patient was initiated on
immunosuppressive therapy using oral
prednisone 45 mg (1 mg/kg) daily and
intravenous pulse cyclophosphamide 1,200 mg
(12 mg/kg/day for 2 days) every 2 weeks.
A month later, the pseudoaneurysm in the
right thoracoacromial artery was hardened and
the CT angiography revealed that the
pseudoaneurysm was shrinking. The levels of
ESR, CRP, IgG, and IgM were gradually reduced
to the normal range. The patient was discharged
on a regimen of azathioprine 100 mg (2 mg/kg)
daily and prednisone 45 mg daily. The dosages
of prednisone and azathioprine were tapered
gradually. After 16 months, prednisone was
reduced to 10 mg every other day. This dose of
prednisone was then continued. After
20 months, azathioprine was reduced to
50 mg/day and discontinued after 30 months.
To date, the pseudoaneurysm has regressed
without recurrence for approximately 2 years
and the patient continues to take prednisone
10 mg every other day.
DISCUSSION
Behcet’s disease with predominant vascular
involvement is known as Vasculo-Behcet’s
disease. It occurs late in the course of Behcet’s
disease and affects males more frequently than
females. Other features of Behcet’s disease, such
as oral and genital ulcerations, skin lesions, and
eye involvement, may not be significant in this
subset of patient, as in the present patient [3].
Four different vascular complications have been
described: arterial occlusion, arterial aneurysm
or pseudoaneurysm, venous thrombosis, and
variceal formation [1]. The aorta is the most
susceptible site for aneurysm, followed by the
pulmonary, femoral, subclavian, popliteal, and
carotid arteries [5].
Fig. 3 Multiple pigmented macules on the neck and backFig. 2 Diffuse inﬂammatory cell inﬁltration in the arterial
wall (original magniﬁcation 9100)
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It is very important to identify patients with
vasculo-Behcet’s disease because they are at risk
of developing recurrent vascular lesions after
the first episode of vascular injury and are prone
to progressive multifocal vessel-related
complications, as in the present patient [6].
Aneurysms are significantly associated with
poor outcome and mainly present acutely with
catastrophic hemorrhage. However, there are
no specific pathognomonic laboratory tests or
histological findings; the diagnosis is based on
typical clinical features and natural history [7].
The present case satisfied the international
criteria for Behcet’s disease [7]. In this case,
though the histological finding showed
nonspecific arteritis, the history of mucosal
ulcerations, cutaneous manifestation, and
positive pathergy test distinguished vasculo-
Behcet’s disease from other vasculitides with
large artery involvement, including Takayasu’s
arteritis, giant cell arteritis, Cogan’s syndrome,
and syphilitic arteritis.
Vasculo-Behcet’s disease is a systemic
autoimmune inflammatory disorder
characterized by vasculitis. Therefore, the aim of
treatment is to control vasculitis and regulate the
immune system. Various therapeutic modalities
have been employed for Behcet’s disease, but the
optimal medical treatment has not been
established, although it predominantly consists
of anti-inflammatory and immunosuppressive
agents [1]. The present patient was treated with
prednisone in combination with
cyclophosphamide and azathioprine to control
active inflammation. Through this therapy, the
levels of ESR, CRP, IgG, and IgM were reduced to
the normal range and the pseudoaneurysm in the
right thoracoacromial artery regressed.
Furthermore, to date, there has not been any
new aneurysm or pseudoaneurysm formation.
Recently, some reports have shown that
infliximab is effective in inducing and
maintaining remission of vasculitic activity in
patients with Behcet’s disease [8]. Infliximab is
also effective in patients who do not respond to
treatment with corticosteroids and
cyclophosphamide [9]. Therefore, in addition
to corticosteroids and cyclophosphamide,
infliximab should be considered as a good
choice in severe vasculo-Behcet’s disease.
Surgical and endovascular interventions are
also important because of the high risk of
aneurismal rupture. Surgical and endovascular
interventions alone for aneurysms are usually
unsuccessful because the incidence of
postoperative complications, such as
anastomotic pseudoaneurysm or stent-graft
thrombosis, is high, as in the present patient
[6]. Some reports have described that surgical
complication is less frequent under the
remission phase of vasculo-Behcet’s disease
than under the active phase [10].
Consequently, surgical and endovascular
treatment is performed ideally in the clinically
inactive period of the disease, and
immunosuppressive treatment after surgery
helps prevent further vasculopathy and
improve the prognosis.
CONCLUSION
In conclusion, an increased awareness of
vasculo-Behcet’s disease and its vascular
complications is essential. Early diagnosis and
early initiation of prednisone in combination
with immunosuppressive therapy are critical for
inhibiting the progression of vascular lesions
and provide a good prognosis.
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